article thumbnail

European PFAS restriction could jeopardise pharmaceutical manufacturing

European Pharmaceutical Review

According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), more than 600 essential medicines are at risk if a proposed restriction on the use of fluorinated substances, per- and polyfluoroalkyl substances (PFAS) across pharmaceutical manufacturing in the EEA, is implemented.

article thumbnail

Elevating pharmaceutical manufacturing processes with real-time insights

European Pharmaceutical Review

These insights help to drive highly efficient manufacturing processes, ensuring competitive product delivery on time and within budget. However, historically, NMR instruments have rarely been deployed during the later stages of pilot testing and manufacturing operations, even when driven by PAT setups.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why prefilled vial capacity is key to a competitive edge in pharmaceuticals manufacturing 

Pharmaceutical Technology

With many biopharma companies outsourcing for manufacturing support, how can your organisation outpace the competition?

article thumbnail

Sustainable energy strategies for pharmaceutical manufacturers

European Pharmaceutical Review

The four governments of the UK established the scheme to increase the climate ambition of the UK’s carbon pricing policy, whilst also protecting the competitiveness of UK businesses. Large energy users such as pharmaceutical manufacturers can play an important role in protecting grid stability while enabling more renewable generation.

article thumbnail

Unleash the Power of AI in GxP Manufacturing

PharmaTech

In pursuit of increased competitiveness and bottom-line impact, pharmaceutical manufacturers face increasing pressure to fast-track technological innovation while maintaining regulatory compliance.

article thumbnail

Innovative pharma-government partnership to enhance UK clinical trials

European Pharmaceutical Review

A major new £400 million public-private collaboration has launched in the UK, aimed at enhancing the life sciences sector’s economic growth and the competitiveness over the next five years. Modernising Health Technology Assessment (HTA) approaches: the final five percent of the investment will aid better access to innovative medicines.

article thumbnail

Unified vision essential in UK advanced manufacturing

European Pharmaceutical Review

Yet these industries have faced disruptions and changes in operating environments, resulting in major challenges to overcome, in addition to a new era of global competition driven by targeted national industrial strategies, according to the ABPI. Combined, these sectors have a turnover of £309 billion, ABPI highlighted.